---
figid: PMC3104361__1743-7075-8-23-1
figtitle: Molecular Pathways of Disease in Familial Hypercholesterolemia (1) The LDL
  receptor on the surface of hepatocytes binds ApoB-100 of the LDL particle forming
  a complex
organisms:
- Homo sapiens
- Diaporthe sclerotioides
organisms_ner:
- Homo sapiens
- Danio rerio
pmcid: PMC3104361
filename: 1743-7075-8-23-1.jpg
figlink: /pmc/articles/PMC3104361/figure/F1/
number: F1
caption: Molecular Pathways of Disease in Familial Hypercholesterolemia (1) The LDL
  receptor on the surface of hepatocytes binds ApoB-100 of the LDL particle forming
  a complex. (2) A clathrin-coated pit is formed and the ligand-receptor complex is
  endocytosed via interactions involving the LDLR Adaptor Protein 1 (LDLRAP1). (3)
  Inside the hepatocyte, the complex dissociates, the LDLR recycles to the cell membrane,
  (4) and free cholesterol is used inside the cell. (5) PCSK9 serves as a post-transcriptional
  inhibitor of LDLR. It is secreted and inhibits LDLR through cell-surface interactions.
  (6) The presence of an intracellular pathway for PCSK9-mediated LDLR inhibition
  is still a subject of controversy. (7) In response to decreased cholesterol such
  as during treatment with statins, Steroid Response Element Binding Protein (SREBP)
  binds to the Steroid Response Element (SRE) on the DNA and induces the transcription
  of the LDLR. (8) The sterol-responsive nuclear receptor LXR on the other hand responds
  to increased intracellular cholesterol inducing the transcription of IDOL, a recently
  discovered molecule that induces the ubiquitin-mediated degradation of the LDLR.
  Clouds in the figure refer to genes in which mutations have been associated with
  increased LDL-C levels.
papertitle: 'Familial Hypercholesterolemia: The Lipids or the Genes?.'
reftext: Akl C Fahed, et al. Nutr Metab (Lond). 2011;8:23-23.
year: '2011'
doi: .na.character
journal_title: .na.character
journal_nlm_ta: .na.character
publisher_name: .na.character
keywords: .na.character
automl_pathway: 0.9482049
figid_alias: PMC3104361__F1
figtype: Figure
redirect_from: /figures/PMC3104361__F1
ndex: ''
seo: CreativeWork
schema-jsonld:
  '@context': https://schema.org/
  '@id': https://pfocr.wikipathways.org/figures/PMC3104361__1743-7075-8-23-1.html
  '@type': Dataset
  description: Molecular Pathways of Disease in Familial Hypercholesterolemia (1)
    The LDL receptor on the surface of hepatocytes binds ApoB-100 of the LDL particle
    forming a complex. (2) A clathrin-coated pit is formed and the ligand-receptor
    complex is endocytosed via interactions involving the LDLR Adaptor Protein 1 (LDLRAP1).
    (3) Inside the hepatocyte, the complex dissociates, the LDLR recycles to the cell
    membrane, (4) and free cholesterol is used inside the cell. (5) PCSK9 serves as
    a post-transcriptional inhibitor of LDLR. It is secreted and inhibits LDLR through
    cell-surface interactions. (6) The presence of an intracellular pathway for PCSK9-mediated
    LDLR inhibition is still a subject of controversy. (7) In response to decreased
    cholesterol such as during treatment with statins, Steroid Response Element Binding
    Protein (SREBP) binds to the Steroid Response Element (SRE) on the DNA and induces
    the transcription of the LDLR. (8) The sterol-responsive nuclear receptor LXR
    on the other hand responds to increased intracellular cholesterol inducing the
    transcription of IDOL, a recently discovered molecule that induces the ubiquitin-mediated
    degradation of the LDLR. Clouds in the figure refer to genes in which mutations
    have been associated with increased LDL-C levels.
  license: CC0
  name: CreativeWork
  creator:
    '@type': Organization
    name: WikiPathways
  keywords:
  - PCSK9
  - COG2
  - LDLRAP1
  - LDLR
  - AOPEP
  - RXRA
  - RXRB
  - RXRG
  - MYLIP
  - KIF23
  - pcsk9
  - ldlra
  - rxrga
  - rxrbb
  - rxrba
  - rxrab
---
